BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
PORT WASHINGTON, N.Y., April 07, 2016 -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Salvatore Guccione, President and CEO, will present at the Needham & Company Healthcare Conference on April 12, 2016 at 5:00 pm ET at the Westin New York Grand Central Hotel.
A webcast of the presentation will be available under Events and Presentations in the investor relations section of the company’s website at www.aceto.com or http://wsw.com/webcast/needham76/acet.
ABOUT ACETO
ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the marketing, sale and distribution of Human Health products (finished dosage form generics and nutritional products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).
Investor Relations Contact: LHA Jody Burfening [email protected] (212) 838-3777
